Chase Doyle

Authored Items

Hospital Readmissions for Venous Thromboembolism a Substantial Cost in Patients with Cancer

March 2019, Vol 9, No 3 - Value-Based Care

Real-world data highlight the significant clinical and economic burden associated with venous thromboembolism (VTE) in patients with cancer. The data come from a study of 12,785 patients hospitalized with acute illnesses, of which 2002 patients had cancer. The results were presented at ASH 2018 and showed that 3.9% of patients with cancer experienced a VTE event requiring rehospitalization—the highest proportion of patients among the study population. Moreover, 28.2% of VTE-related readmissions occurred within the first 30 days of initial hospital discharge. [ Read More ]

Do No Financial Harm: How to Improve Cost Transparency in Cancer Care

February 2019, Vol 9, No 2 - Financial Toxicity

We’ve heard the figures before: the price of cancer drugs has risen by orders of magnitude per month over the past decades, deductibles have tripled in the past 6 years, and employer contribution to premiums has increased by nearly 300% over the past 15 years. In addition to cancer treatment becoming more expensive, insurance design and drug formularies have changed, resulting in a greater financial burden for patients. [ Read More ]

Timing of Palliative Care Consults Key in Elderly Patients with Pancreatic Cancer

September 2018, Vol 8, No 9 - Palliative Care

A claims analysis of elderly patients with pancreatic cancer has shown that those receiving early palliative care consultations had lower healthcare utilization than patients who received late palliative care. Data presented at ASCO 2018 showed that patients who received palliative care within 4 weeks of diagnosis had fewer visits to the emergency department (2.4 vs 3.0, respectively; P <.001) and lower emergency department–related costs ($3043 vs $4117, respectively). [ Read More ]

Discussing Costs with Your Patient Can Reduce Financial Toxicity

July 2018, Vol 8, No 7 - Financial Support

With healthcare premiums on the rise and out-of-pocket costs skyrocketing, almost every person diagnosed with cancer is at risk for being underinsured, but this threat extends beyond a patient’s bank balance. Recent research has shown that when patients face extreme financial distress, they have a greater risk for worse outcomes, including mortality. At the 2018 American Society of Clinical Oncology meeting, Yousuf Zafar, MD, MHS, Director, Center for Applied Cancer Health Policy, Duke Cancer Institute, Durham, NC, discussed the need to prevent financial toxicity at the patient level by focusing on high-value interventions. [ Read More ]

Recent FDA Approvals for Acute Lymphoblastic Leukemia a “Watershed” Moment

March 2018, Vol 8, No 3 - Hematologic Malignancies

The past few years have witnessed significant progress in the treatment of several hematologic malignancies, and truly paradigm-changing therapies have recently emerged in acute lymphoblastic leukemia (ALL). At ASH 2017, Crystal L. Mackall, MD, Co-Director, Immunology & Immunotherapy of Cancer Program, Stanford University, CA, discussed the FDA approvals of 2 important treatments for patients with B-cell precursor ALL. [ Read More ]

Survey Highlights Need for Improved Patient–Provider Communication and Symptom Management

March 2018, Vol 8, No 3 - Provider–Patient Communication

Patients with chronic myeloid leukemia (CML) may be living longer thanks to improved therapies, but the results of a new study suggest that they are burdened by ongoing symptoms and treatment side effects. According to data presented at ASH 2017, fatigue, muscle aches, sleep disturbance, and memory loss were reported by 70%, 57%, 46%, and 42% of patients, respectively. [ Read More ]

Using Goals-of-Care Videos Can Revolutionize End-of-Life Decisions

March 2018, Vol 8, No 3 - Palliative Care

A recent survey by Consumer Reports shows that nearly 90% of Americans prefer to die at home, focused on comfort, and yet 66% of Americans aged >65 years die in a healthcare setting, intubated and in considerable pain. According to Angelo E. Volandes, MD, MPH, Internal Medicine Physician, Massachusetts General Hospital, Boston, this misalignment between the medical care people want and the care they ultimately receive is the most urgent problem in American healthcare today. [ Read More ]

Utilization of Palliative Care “Dismal” for Patients with Hematologic Malignancies

March 2018, Vol 8, No 3 - Hematologic Malignancies, Palliative Care

The largest-ever study of palliative care trends has shown the use of palliative care services to be “sporadic at best” for patients with hematologic malignancies. According to the review of nearly 300,000 patients, there was also significant heterogeneity in practice patterns, including National Cancer Institute (NCI)-designated practices, across all characteristics studied. [ Read More ]

Oncologists Don’t Have the Luxury of Not Discussing Financial Toxicity with Patients

September 2017, Vol 7, No 9 - Value-Based Care

Chicago, IL—The issues underlying financial toxicity are undoubtedly complex, but for oncologists looking to help their patients cope, simply noting the cost of treatment from the outset may be the best place to start. As the cost of cancer care continues to rise, greater transparency throughout the process of drug pricing and drug payment needs to become part of the clinical discussion, said Leonard Saltz, MD, Chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2017 ASCO annual meeting. [ Read More ]

Optimizing the Alignment of Value and Precision Medicine in Oncology

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017 - Precision Medicine

Chicago, IL—As healthcare resources become increasingly constrained, aligning precision medicine and value may offer a way forward, but traversing this path could be a challenge for oncologists. According to Deborah Schrag, MD, MPH, Chief, Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, the vision of precision medicine is for accurate biomarkers to identify the appropriate candidates for targeted treatment, which is more effective and less toxic than traditional cytotoxic chemotherapy. Given the rapid pace of innovation, however, the reality is more complex. [ Read More ]

FDA Perspective on Safety Reporting of Serious Adverse Events

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017 - Adverse Events

Chicago, IL—Although regulations state that sponsors are required to notify the US Food and Drug Administration (FDA) of potential serious risks from clinical trials, the large volume of adverse event report submissions has been identified as a burden to the effective conduct of clinical research, reported Meredith K. Chuk, MD, Medical Officer, FDA Office of Hematology and Oncology Products (OHOP), Silver Spring, MD, at the 2017 ASCO annual meeting practice management sessions. [ Read More ]

Improving Communication Skills to Address Patient Goals Related to End-of-Life Care

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017 - Communication Skills, End-of-Life Care

Chicago, IL—As palliative care assumes a larger role in clinical practice, talking with patients about their goals of care, especially early in the disease course, is more important than ever. In fact, according to Anthony L. Back, MD, Co-Director, Cambia Palliative Care Center of Excellence, University of Washington, Seattle, having conversations about end-of-life and supportive care is one of the critical competencies that every oncologist and cancer care clinician needs to take into consideration. [ Read More ]

Patient-Reported Outcomes and New Technologies

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017 - Social Media/New Technologies

Chicago, IL—Patient-reported outcomes (PROs) have not been around for long, but they have been involved in nearly every aspect of oncology. Monitoring PROs has the potential to improve clinical benefit, more accurately capture toxicity, and provide better cost data. In addition, new technologies can facilitate the collection of PROs and other patient-generated data, said Heather S. Jim, PhD, Associate Member, Moffitt Cancer Center, Tampa, FL, at the 2017 ASCO annual meeting practice management sessions. [ Read More ]

Social Media a Powerful Tool for Communicating and Networking in Oncology

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017 - Social Media/New Technologies

Chicago, IL—Social media is not only for teenagers, and this platform has expanded more than its user base. In the past decade, social media has evolved to become a powerful tool of communication for professionals, and this is especially true in the healthcare world. At the 2017 ASCO annual meeting practice management sessions, Merry Jennifer Markham, MD, FACP, Associate Professor, Division of Hematology and Oncology, University of Florida, Gainesville, shared examples of how social media can be used for professional development and networking while also describing potential barriers to its use. [ Read More ]

Business of Practice 2017: Maximize Your MIPS Success

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017 - Professional Development, Reimbursement Issues

Chicago, IL—As the battle over the Affordable Care Act rages on, Congress remains steadfast in its support of the Quality Payment Program. Even though Medicare reimbursement will not change until 2019, the new era of the Quality Payment Program begins this year. At the 2017 ASCO annual meeting practice management sessions, Stephen S. Grubbs, MD, FASCO, ASCO’s Vice President of Clinical Affairs, described the requirements of the Quality Payment Program and shared strategies for optimal reporting. [ Read More ]

Oncology Practice in a Shifting Policy Landscape: The Role of State Affiliates

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017 - Oncology Policy

Chicago, IL—For the past 5 years, state affiliates have become galvanized by the issues facing oncologists, especially with the increased involvement and support of ASCO, said Tracey Weisberg, MD, President and Lead Physician, New England Cancer Specialists, Scarborough, ME, and Chair, ASCO State Affiliate Council, at the 2017 ASCO annual meeting practice management sessions. Dr Weisberg encouraged members to join their respective state societies and outlined the high-priority issues that have shaped recent discussions. [ Read More ]

Clinical Pathways: Agents of Change Toward Patient-Centric Care

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017 - Clinical Pathways

Chicago, IL—Developed in the early 2000s, clinical pathways are being increasingly used by providers. According to ASCO’s The State of Cancer Care in America, 2016 report, there was a 46% increase in the provider use of clinical pathways between 2014 and 2015, and that figure now exceeds 50%, reported Robin Zon, MD, FACP, FASCO, Medical Oncologist, Michiana Hematology Oncology Advanced Centers for Cancer Care, South Bend, IN, and Chair of the ASCO Task Force on Clinical Pathways, at the 2017 ASCO annual meeting. Dr Zon described the potential role of high-quality clinical pathways in payment reform and utilization management and forecasted the future of clinical pathways, with possible returns on investment. [ Read More ]

What Do We Still Need to Know About Adolescent and Young Adult Survivorship?

May 2017, Vol 7, No 5 - Survivorship

As a result of the differences in biology, access to care, and psychosocial and socioeconomic circumstances, adolescent and young adult (AYA) patients with cancer face distinct challenges compared with their adult counterparts. At the 2017 Cancer Survivorship Symposium, Emily S. Tonorezos, MD, MPH, General Internist, Adult Long-Term Follow-Up Program, Memorial Sloan Kettering Cancer Center, New York, NY, discussed gaps in research and treatment in this vulnerable patient population, while proposing solutions to improve AYA survivorship care. [ Read More ]

Reducing Disparities in Survivorship Care

April 2017, Vol 7, No 4 - Survivorship

Surviving cancer is the start of a new journey for many individuals. Cancer survivors face a multitude of challenges, including the prevention of new and recurrent cancers; interventions for illnesses secondary to cancer and its treatment; concerns about employment, insurance, and disability; and coordination between specialists and primary care providers. These challenges are compounded by the need to ensure appropriate, culturally sensitive delivery of care to vulnerable patient populations, said Margaret Q. Rosenzweig, PhD, FNP-BC, AOCNP, FAAN, Professor of Acute and Tertiary Care, University of Pittsburgh School of Nursing, PA, at the 2017 Cancer Survivorship Symposium. [ Read More ]

Rapid Adoption of Novel Oncology Drugs Improves Overall Survival

April 2017, Vol 7, No 4 - Survivorship

Innovation takes time, especially when it comes to cancer research. However, delays in the adoption of novel oncology treatments can have a significant impact on patient health, reported Jason Shafrin, PhD, Director of Healthcare Quality and Value-Based Research Methods, and Senior Research Economist, Precision Health Economics, Los Angeles, CA, who presented the results of a geographic-based analysis of claims data at the 2017 Cancer Survivorship Symposium. [ Read More ]

New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs

February 2017, Vol 7, No 2 - ASH 2016 Highlights

A new economic model suggests that overall survival and drug toxicity profiles are insufficient for assessing the value of a drug. According to a study that incorporated late adverse events in advanced Hodgkin lymphoma, a more comprehensive benefit-to-risk ratio of a drug requires an understanding of its long-term health implications, said Ohad Oren, MD, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, at the 2016 American Society of Hematology meeting. [ Read More ]

Measuring Outcomes to Improve Quality

March 2016, Vol 6, No 3 - Reimbursement

Medicare is poised to incorporate new quality metrics as a guide for payments. At ASH 2015, Helen Burstin, MD, MPH, Chief Scientific Officer, National Quality Forum, Washington, DC, discussed the need for measures and reporting systems that reflect patient care and care coordination. “The purpose of measurement is [ Read More ]

Cost of Regorafenib versus Benefit Analyzed in Patients with Metastatic Colorectal Cancer

April 2015, Vol 5, No 3 - Gastrointestinal Cancers Symposium

According to a recent cost-effectiveness analysis, third-line therapy with regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer (CRC) far ­exceeded accepted willingness-to-pay thresholds based on incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALYs). Presented at the 2015 Gastrointestinal [ Read More ]